Illumina, Inc.

Illumina launches advanced liquid biopsy assay to enable comprehensive genomic profiling of solid tumors

Retrieved on: 
Wednesday, November 1, 2023
MIT EAD Airframe Version 2, Pathology, Non-small-cell lung cancer, Medical laboratory, CGP, Nucleic acid thermodynamics, Research, Circulating tumor DNA, Illumina, Inc., Medicine, National Cancer Institute, TSO, Blood, Workflow, University, Chemistry, Liquid biopsy, Neoplasm, SAN, DNA, Automation, Medical imaging, Food delivery, Illumina

SAN DIEGO, Nov. 1, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a new generation of its distributed liquid biopsy assay for genomic profiling. The new TruSight™ Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) is a research assay that enables noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) from blood when tissue testing is not available, or to complement tissue-based testing.

Key Points: 
  • SAN DIEGO, Nov. 1, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a new generation of its distributed liquid biopsy assay for genomic profiling.
  • The new TruSight™ Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) is a research assay that enables noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) from blood when tissue testing is not available, or to complement tissue-based testing.
  • Growing evidence on the utility and efficacy of liquid biopsy CGP is leading to its inclusion in recommended professional guidelines in oncology.
  • Most notably, liquid biopsy testing in non-small-cell lung cancer has proven useful when tissue results are either unavailable or delayed.

Revvity, Inc. and Element Biosciences, Inc. Pioneer Next-Generation Sequencing Kits Market with Innovative Genomic Analysis Solutions

Retrieved on: 
Wednesday, October 18, 2023
WHO, Laboratory, Data analysis, DSM-IV codes, Sickle cell disease, Next, Genetics, Conditional sentence, Organization, Research, Illumina, Inc., Genomics, Growth, NGS, World Health Organization, Partnership, Cystic fibrosis, Workflow, Infection, Agilent Technologies, Cancer, Collection, Patient, Death, DNA, Stanford University School of Medicine, Retail, Vaccine, Illumina

The "Next Generation Sequencing Kits Market " report added to ResearchAndMarkets.com's offering provides valuable insights into this groundbreaking advancement.

Key Points: 
  • The "Next Generation Sequencing Kits Market " report added to ResearchAndMarkets.com's offering provides valuable insights into this groundbreaking advancement.
  • Genomic data, generated by next-generation sequencing (NGS), has become an essential driving force behind scientific innovation and research.
  • The global Next Generation Sequencing Kits market is segmented based on workflow, sequencing type, usage area, application, and end users.
  • Several prominent players are at the forefront of driving innovation in the Global Next Generation Sequencing Kits Market.

Lowey Dannenberg, P.C. is Investigating Illumina, Inc. (NASDAQ: ILMN) for Potential Breaches of Fiduciary Duty by Its Board of Directors

Retrieved on: 
Wednesday, October 4, 2023
Illumina, Inc., Financial adviser, Security (finance), Illumina

NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating a potential breach of fiduciary duty claim involving the board of directors of Illumina, Inc. (NASDAQ: ILMN) (“Illumina”).

Key Points: 
  • NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating a potential breach of fiduciary duty claim involving the board of directors of Illumina, Inc. (NASDAQ: ILMN) (“Illumina”).
  • If you are a long-term shareholder of Illumina, and wish to participate, learn more, or discuss the issues surrounding the investigation, please contact Andrea Farah at [email protected] or (914) 733-7256.

Broken String Biosciences Strengthens Senior Leadership Team to Accelerate Product Development and Commercialization

Retrieved on: 
Monday, October 2, 2023
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Acceleration, University of Oxford, Trade, Broken String, Central New York Regional Market, NGS, Gene editing, Genomics, Doctor of Philosophy, Chemistry, Vincent Smith, Traction, Broken, Consumables, Commercial, Vince, Imperial College London, Management, Vaccine, Illumina, Inc., Illumina, Biochemistry

As CTO at Broken String, Vince will lead product development, providing leadership and the expertise required to build INDUCE-seq into the gold standard technology for the assessment of off-target effects during gene editing.

Key Points: 
  • As CTO at Broken String, Vince will lead product development, providing leadership and the expertise required to build INDUCE-seq into the gold standard technology for the assessment of off-target effects during gene editing.
  • Jessica will oversee the development of commercialization strategy, enabling the Company to capitalize on early commercial traction and accelerate growth across the US, Europe and Asia.
  • Before joining Broken String, Jessica held several senior leadership roles, including Senior Director of Sales and Regional Marketing at Bionano, Senior Director of Commercial Development at Synthego and Chief Commercial Officer at 54gene.
  • Jessica Rich, VP Business Development at Broken String Biosciences, said: "I am excited to join the team at Broken String Biosciences and to expand the global commercial footprint from my base in Boston, MA.

Lowey Dannenberg, P.C. is Investigating Illumina, Inc. (NASDAQ: ILMN) for Potential Breaches of Fiduciary Duty by Its Board of Directors

Retrieved on: 
Friday, September 29, 2023
Illumina, Inc., Financial adviser, Security (finance), Illumina

NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating a potential breach of fiduciary duty claim involving the board of directors of Illumina, Inc. (NASDAQ: ILMN) (“Illumina”).

Key Points: 
  • NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating a potential breach of fiduciary duty claim involving the board of directors of Illumina, Inc. (NASDAQ: ILMN) (“Illumina”).
  • If you are a long-term shareholder of Illumina, and wish to participate, learn more, or discuss the issues surrounding the investigation, please contact Andrea Farah at [email protected] or (914) 733-7256.

Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials

Retrieved on: 
Tuesday, September 19, 2023
DNA, Partnership, Myriad Genetics, HRD, Head, MYGN, TSO, Research, RNA, SALT, Genetics, Patient, Illumina, Inc., Medicine, Genetic testing, IVD, CDX, Gene, Myriad, Vaccine, Illumina

Under the strategic partnership, Myriad and Illumina are working together to advance comprehensive genomic profiling plus homologous recombination deficiency (HRD) testing using the globally distributed Illumina TruSight Oncology 500 (TSO 500) assay, which enables comprehensive genomic profiling by analyzing 523 genes across DNA and RNA variants.

Key Points: 
  • Under the strategic partnership, Myriad and Illumina are working together to advance comprehensive genomic profiling plus homologous recombination deficiency (HRD) testing using the globally distributed Illumina TruSight Oncology 500 (TSO 500) assay, which enables comprehensive genomic profiling by analyzing 523 genes across DNA and RNA variants.
  • The second milestone involves Myriad’s initiation of its first reproducibility test project to support future regulatory filings for TSO Comp.
  • Myriad now provides support in Illumina’s partnerships with pharmaceutical companies to develop companion diagnostics on TSO Comp.
  • “These key milestones empower Myriad to accelerate the pace of research and scientific innovation to support the advancement of cancer care for patients,” said Paul Bartel, senior vice president of companion diagnostics, Myriad Genetics.

NGS Technologies Paving the Way for Personalized Medicine: Key Insights Unveiled in Comprehensive Market Analysis - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 21, 2023
Technology, Biotechnology, Chemicals, Plastics, Health, Manufacturing, Pharmaceutical, Artificial Intelligence, Oncology, Other Science, Other Technology, Research, Genetics, Science, Clinical Trials, Drug development, NGS, Gene expression, Biomarker, AstraZeneca, Compound annual growth rate, Illumina, Inc., Drug discovery, Growth, Massive parallel sequencing, Gene, Safety, Geography, Fine chemical, Pharmaceutical industry, Antibiotics

The latest market analysis reveals a promising trajectory for the global Next-Generation Sequencing (NGS) in Drug Development market.

Key Points: 
  • The latest market analysis reveals a promising trajectory for the global Next-Generation Sequencing (NGS) in Drug Development market.
  • This growth is propelled by the transformative potential of NGS technologies in revolutionizing genetic research and advancing drug development.
  • The comprehensive report explores a wide spectrum of NGS technologies, applications, industries, initiatives, patents, and key market players.
  • It meticulously delineates market dynamics for NGS in drug development, offering insights into the years 2020, 2021, 2022, 2023, and the promising horizon of 2028.

Advancements in Molecular Diagnostics Fuel Nucleic Acid Isolation Market with 8.5% CAGR Forecast Amid Rising Demand for High-Quality Nucleic Acids - ResearchAndMarkets.com

Retrieved on: 
Monday, September 18, 2023
Biotechnology, Pharmaceutical, Genetics, Health, QIAGEN, NGS, Genetic testing, Research, Thermo Fisher Scientific, DSM-IV codes, RNA, Automation, Genomics, Government, DNA, Microfluidics, Compound annual growth rate, Promega, Traction, Investment, Agilent Technologies, Vels Institute of Science, Technology & Advanced Studies, Growth, Robotics, Reagent, Illumina, Inc., Fine chemical, Pharmaceutical industry, Vaccine, Pet industry, Phosphorus, Instrument

The nucleic acid isolation and purification market is poised for significant growth with a projected Compound Annual Growth Rate (CAGR) of 8.5% during the forecast period from 2023 to 2031.

Key Points: 
  • The nucleic acid isolation and purification market is poised for significant growth with a projected Compound Annual Growth Rate (CAGR) of 8.5% during the forecast period from 2023 to 2031.
  • Molecular diagnostic tests for various diseases rely on efficient nucleic acid isolation and purification techniques.
  • Type of Nucleic Acid: Segmented into DNA Isolation & Purification and RNA Isolation & Purification, with RNA purification anticipated to grow rapidly.
  • Key Questions Answered in the Report:
    What factors are impacting the growth of the nucleic acid isolation and purification market?

Illumina: Company Investigated by the Portnoy Law Firm

Retrieved on: 
Tuesday, September 5, 2023
Illumina, Inc., Illumina

LOS ANGELES, Sept. 05, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Illumina, Inc. ("Illumina" or "the Company") (NASDAQ:ILMN) investors that the firm has initiated an investigation into possible securities violations and may file a class action on behalf of investors. Illumina investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.

Key Points: 
  • LOS ANGELES, Sept. 05, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Illumina, Inc. ("Illumina" or "the Company") (NASDAQ:ILMN) investors that the firm has initiated an investigation into possible securities violations and may file a class action on behalf of investors.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • The company is being investigated for potential breaches of fiduciary duty on the part of its directors and management.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.

Illumina's Board Appoints Jacob Thaysen, Ph.D. as its New Chief Executive Officer

Retrieved on: 
Tuesday, September 5, 2023
Informatics, DNA, Technical University of Denmark, Diagnosis, General counsel, Master of Science, Genomics, Institute of technology, Research, Agilent Technologies, SAN, Physics, Growth, Illumina, Inc., Management, Illumina

Since 2018, he has overseen the unit responsible for Agilent's market-leading analytical instrument portfolio, informatics, and cell analysis franchise.

Key Points: 
  • Since 2018, he has overseen the unit responsible for Agilent's market-leading analytical instrument portfolio, informatics, and cell analysis franchise.
  • In 2022, that division, Agilent's largest, had revenue of approximately $4 billion, more than 50,000 customers, and an operating margin of approximately 30%.
  • "I want to thank Chuck for his invaluable contribution as interim CEO during this important transition," said Mr. MacMillan.
  • "We asked Chuck to take on this role, and he has served the company well over the last few months."